[1]CurrentPatentAssignee:BIGESPAS-WO2022/160066,2022,A1Locationinpatent:Paragraph0071-0072
[2]CurrentPatentAssignee:PFIZERINC-WO2009/111540,2009,A1Locationinpatent:Page/Pagecolumn27-28
[3]CurrentPatentAssignee:ACADEMYOFMILITARYMEDICALSCIENCES-EP2417973,2012,A1Locationinpatent:Page/Pagecolumn7;9;17
[4]CurrentPatentAssignee:ACADEMYOFMILITARYMEDICALSCIENCES-US2012/122914,2012,A1Locationinpatent:Page/Pagecolumn6
[5]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-US2010/125085,2010,A1Locationinpatent:Page/Pagecolumn18
[1]CurrentPatentAssignee:PFIZERINC-WO2011/39670,2011,A1Locationinpatent:Page/Pagecolumn56-57
[1]Locationinpatent:experimentalpartAlekseyev;Ivanov;Kurkin;Yurovskaya[ChemistryofHeterocyclicCompounds,2011,vol.46,#10,p.1239-1249]
[1]Alekseyev;Ivanov;Kurkin;Yurovskaya[ChemistryofHeterocyclicCompounds,2011,vol.46,#10,p.1239-1249]
Title: Glutamate receptor modulator dimebon stimulates consolidation and reconsolidation of weak memory in chicks.
Journal: Bulletin of experimental biology and medicine 20120901
Title: Anhedonic-like traits and lack of affective deficits in 18-month-old C57BL/6 mice: Implications for modeling elderly depression.
Journal: Experimental gerontology 20120801
Title: Dimebon slows progression of proteinopathy in γ-synuclein transgenic mice.
Journal: Neurotoxicity research 20120701
Title: Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission.
Journal: Psychiatria Danubina 20120601
Title: Dimebon attenuates methamphetamine, but not MPTP, striatal dopamine depletion.
Journal: Neurochemistry international 20120601
Title: The acute effects of dimebolin, a potential Alzheimer's disease treatment, on working memory in rhesus monkeys.
Journal: British journal of pharmacology 20111001
Title: Latrepirdine increases cerebral glucose utilization in aged mice as measured by [18F]-fluorodeoxyglucose positron emission tomography.
Journal: Neuroscience 20110825
Title: Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.
Journal: Neuro-degenerative diseases 20110801
Title: Drugs: a tangled web of targets.
Journal: Nature 20110713
Title: Dimebolin in dementia.
Journal: CNS neuroscience & therapeutics 20110601
Title: Ruthenium-catalyzed γ-carbolinium ion formation from aryl azides; synthesis of dimebolin.
Journal: Organic letters 20110520
Title: [Geroprotective properties of dimebon: morphological characterization of organs and tissues in mice after long-term treatment].
Journal: Eksperimental'naia i klinicheskaia farmakologiia 20110101
Title: The rise and fall of Dimebon.
Journal: Drug news & perspectives 20101001
Title: Investigational medications for treatment of patients with Alzheimer disease.
Journal: The Journal of the American Osteopathic Association 20100901
Title: [Drug therapy for Alzheimer's disease].
Journal: Brain and nerve = Shinkei kenkyu no shinpo 20100701
Title: Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.
Journal: The Journal of pharmacology and experimental therapeutics 20100601
Title: From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon.
Journal: Current Alzheimer research 20100301
Title: Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.
Journal: Bioorganic & medicinal chemistry letters 20100101
Title: Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death.
Journal: Journal of Alzheimer's disease : JAD 20100101
Title: Synthesis and biological evaluation of novel 5,8-disubstituted-2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b] indoles as 5-HT(6) and H(1) receptors antagonists.
Journal: Archiv der Pharmazie 20091201
Title: Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities.
Journal: Biochemical pharmacology 20091015
Title: Dimebon as a potential therapy for Alzheimer's disease.
Journal: CNS spectrums 20090801
Title: Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.
Journal: Bioorganic & medicinal chemistry letters 20090615
Title: [Progress in the research on multi-target-directed drugs against Alzheimer's disease].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20090301
Title: [Therapy of Alzheimer disease].
Journal: Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20090301
Title: Alzheimer's disease: on the verges of treatment and prevention.
Journal: The Lancet. Neurology 20090101
Title: Progress in Alzheimer's disease drug discovery: an update.
Journal: Current opinion in investigational drugs (London, England : 2000) 20090101
Title: A promising new treatment for Alzheimer's disease?
Journal: The Lancet. Neurology 20080901
Title: Current and future therapy in Alzheimer's disease.
Journal: Fundamental & clinical pharmacology 20080601
Title: [Mitochondria as the target for neuroprotectors].
Journal: Vestnik Rossiiskoi akademii meditsinskikh nauk 20050101
Title: Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons.
Journal: Bulletin of experimental biology and medicine 20031101
Title: Mitochondria as a target for neurotoxins and neuroprotective agents.
Journal: Annals of the New York Academy of Sciences 20030501
Title: Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer.
Journal: Annals of the New York Academy of Sciences 20010601
Title: Steele JW, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry. 2013 Aug;18(8):889-97.
